VIDEO: AMD, geographic atrophy treatments advance with FDA approvals, recent innovations

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Certainly, particularly in pharmacotherapy Last year marked a significant milestone with the introduction of the first ever two FDA-approved medications for geographic atrophy. Prior to this, treatment options for this patient population were very limited. These new treatments offer promising outcomes by substantially slowing down the progression of the disease and with long-term follow-up data showing even better and more encouraging results. There have also been notable developments in the treatment of wet age-related macular degeneration with the FDA approval of two new medications. Now, one is a combination therapy targeting both vascular endothelial growth factor and Ang-2, while the other one is a high-dose formulation of a well-established medication. Both of these medications demonstrated great efficacy and improved durability, and obviously they’re offering a new hope for our patients. The introduction of biosimilars into the field last year also has provided additional treatment options for our patients, and it’s showing some promising results as well. One particularly promising avenue in AMD treatment is gene therapy. Numerous ongoing clinical trials are exploring this approach, and there is eager anticipation for the interim results. Gene therapy holds the potential to revolutionize AMD treatment, offering the prospect of targeted intervention early in the course of the disease and also offering long-lasting benefits for patients.